AstraZeneca vs BP: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: AstraZeneca and BP side by side

1. 1901BP

   D'Arcy Persian Concession

   William Knox D'Arcy obtains a 60-year oil concession from the Shah of Persia covering about 480,000 square miles, roughly three-quarters of the country, in exchange for £20,000 in cash, £20,000 in shares and 16% of annual profits.

2. 1908BP

   Discovery of Oil at Masjid-i-Suleiman

   After seven years of expensive and largely unsuccessful drilling, field manager George Reynolds strikes oil at Masjid-i-Suleiman in south-west Persia on May 26, 1908. It is the first commercial oil discovery in the Middle East.

3. 1909BP

   Anglo-Persian Oil Company Incorporated

   The Anglo-Persian Oil Company is formally incorporated in April 1909, with William Knox D'Arcy and the Burmah Oil Company as principal backers.

4. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

5. 1914BP

   British Government Acquires 51% Stake

   At the urging of Winston Churchill, First Lord of the Admiralty, the British government pays ~$2.9 million (£2.2 million) for a 51% stake in Anglo-Persian and signs a long-term fuel-oil supply contract for the Royal Navy, which is converting its fleet from coa…

6. 1954BP

   Renamed British Petroleum

   Following the 1953 resolution of the Iranian nationalization crisis and the Shah's restoration to power, the company renames itself British Petroleum Company.

7. 1970BP

   North Sea Forties Field Discovery

   BP discovers the Forties field in the UK North Sea, one of the largest oil fields ever found in British waters. Together with Alaska's Prudhoe Bay, it gives BP politically secure production just as Middle Eastern governments take control of their oil.

8. 1987BP

   UK Government Privatization Complete

   The Thatcher government completes the privatization of its remaining 31.5% stake in BP through a global share offering timed for October 1987 weeks before the global stock market crash known as Black Monday disrupted the sale and left underwriters with unsold…

9. 1993AstraZeneca

   Zeneca Group Spun Off from ICI

   Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

10. 1998BP

    Merger with Amoco Corporation

    BP merges with Chicago-based Amoco Corporation in a deal valued at approximately $48.2 billion the largest industrial merger in history at the time.

11. 1999AstraZeneca

    Astra and Zeneca Merge to Form AstraZeneca

    The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

12. 2000AstraZeneca

    Nexium Launch Replaces Prilosec

    AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

13. 2000BP

    Beyond Petroleum Rebrand

    Under then-CEO Sir John Browne, BP launches the 'Beyond Petroleum' rebranding campaign, introducing the sunflower logo still in use today and publicly positioning the company as an energy company committed to addressing climate change.

14. 2006AstraZeneca

    Acquisition of Cambridge Antibody Technology

    AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

15. 2007AstraZeneca

    Acquisition of MedImmune for $15.6 Billion

    AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

16. 2010BP

    Deepwater Horizon Disaster

    The Deepwater Horizon drilling rig, operating on the Macondo well in the Gulf of Mexico under contract to BP, suffers a catastrophic blowout on April 20, 2010, killing 11 workers and triggering the largest marine oil spill in US history approximately 4.9 milli…

17. 2012AstraZeneca

    Pascal Soriot Appointed CEO

    Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

18. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

19. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

20. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

21. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

22. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

23. 2020BP

    Net-Zero Commitment and Dividend Cut

    Under new CEO Bernard Looney, BP sets a net-zero ambition for 2050 and, in August 2020, pledges to cut oil and gas production by 40% by 2030 and raise low-carbon investment to about $5 billion a year.

24. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

25. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

26. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

27. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

28. 2024BP

    Auchincloss Confirmed as CEO

    Murray Auchincloss, BP's CFO since 2020 and interim chief since Bernard Looney's September 2023 exit, is confirmed as permanent CEO in January 2024.

29. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

30. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

31. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

32. 2025BP

    Strategy Reset and Bumerangue Discovery

    In February 2025 BP cuts planned transition investment to $1.5-2 billion a year, raises upstream spending to about $10 billion a year and targets $20 billion of divestments and $14-18 billion of net debt by 2027.

33. 2025BP

    CEO Change and Castrol Sale Agreed

    On December 17, 2025 BP says Murray Auchincloss will step down and names Woodside Energy CEO Meg O'Neill as his successor from April 2026, with Carol Howle as interim CEO.

34. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

35. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

36. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

37. 2026BP

    O'Neill Takes Over and Simplifies BP

    Meg O'Neill becomes CEO on April 1, 2026. The board removes chair Albert Manifold on May 26 over governance and conduct concerns and names Ian Tyler interim chair, confirming him as permanent chair on September 2.

Acquisitions

Questions about AstraZeneca vs BP